PMC:6640909 / 34998-37996
Annnotations
TEST0
{"project":"TEST0","denotations":[{"id":"31100109-210-217-7342","span":{"begin":490,"end":493},"obj":"[\"23849522\"]"},{"id":"31100109-237-243-7343","span":{"begin":706,"end":708},"obj":"[\"23352391\"]"},{"id":"31100109-9-16-7344","span":{"begin":710,"end":713},"obj":"[\"17164018\"]"},{"id":"31100109-235-242-7345","span":{"begin":1282,"end":1285},"obj":"[\"23849522\"]"},{"id":"31100109-10-17-7346","span":{"begin":1287,"end":1290},"obj":"[\"24332922\"]"},{"id":"31100109-15-22-7347","span":{"begin":1292,"end":1295},"obj":"[\"24621873\"]"},{"id":"31100109-8-15-7348","span":{"begin":1386,"end":1389},"obj":"[\"28087104\"]"},{"id":"31100109-9-16-7349","span":{"begin":1556,"end":1559},"obj":"[\"22727248\"]"},{"id":"31100109-234-239-7350","span":{"begin":1715,"end":1716},"obj":"[\"27207191\"]"},{"id":"31100109-8-15-7351","span":{"begin":1718,"end":1721},"obj":"[\"20200382\"]"},{"id":"31100109-238-243-7352","span":{"begin":1812,"end":1813},"obj":"[\"27207191\"]"},{"id":"31100109-8-15-7353","span":{"begin":1815,"end":1818},"obj":"[\"20200382\"]"},{"id":"31100109-238-243-7354","span":{"begin":2014,"end":2015},"obj":"[\"27207191\"]"},{"id":"31100109-224-230-7355","span":{"begin":2017,"end":2019},"obj":"[\"23352391\"]"},{"id":"31100109-12-19-7356","span":{"begin":2021,"end":2024},"obj":"[\"21037469\"]"},{"id":"31100109-234-241-7357","span":{"begin":2451,"end":2454},"obj":"[\"28320259\"]"},{"id":"31100109-10-17-7358","span":{"begin":2456,"end":2459},"obj":"[\"28316276\"]"},{"id":"31100109-215-222-7359","span":{"begin":2989,"end":2992},"obj":"[\"23531278\"]"},{"id":"31100109-220-227-7360","span":{"begin":2994,"end":2997},"obj":"[\"17617902\"]"}],"text":"Recommendation Class Level References\nMonitoring\nIn postoperative patients with mechanical circulatory support, continuous electrocardiography, pulse oximetry, central venous pressure and invasive arterial blood pressure monitoring are recommended. I C\nMiniaturized transoesophageal echocardiographic probes that can be maintained in the oesophagus in situ for up to 72 h may be considered to assist in the management of fluid resuscitation and to diagnose complications. IIb C [317]\nA pulmonary artery catheter should be considered to assist in the management of fluid resuscitation and to diagnose complications in patients receiving an LVAD and at risk of postoperative RV failure. IIa C [71, 318]\nTranspulmonary thermodilution and pulse contour-derived measurement of cardiac output are inadequate in continuous-flow ventricular assist device and biventricular assist device settings and are therefore not recommended. III C\nPostoperative laboratory monitoring, including daily measurement of plasma free haemoglobin and lactate dehydrogenase, is recommended. I C\nRight ventricular failure in patients with a left ventricular assist device\nRegular echocardiographic scans should be considered to monitor RV function in patients supported by an LVAD. IIa C [317, 319, 320]\nEchocardiography is recommended to guide weaning from temporary RV support. I B [321, 322]\nInhaled NO, epoprostenol (or prostacyclin) and phosphodiesterase 5 inhibitors may be considered to reduce right heart failure after LVAD implantation. IIb C [323–327]\nInotrope and vasopressor support\nNorepinephrine should be considered as a first-line vasopressor in case of postoperative hypotension or shock. IIa B [9, 328, 329]\nDopamine may be considered in case of postoperative hypotension or shock. IIb B [9, 328, 329]\nThe combination of norepinephrine and dobutamine should be considered instead of epinephrine in case of postoperative hypotension and low cardiac output syndrome with RV failure. IIa C [9, 71, 330, 331]\nEpinephrine may be considered in case of postoperative hypotension and low cardiac output syndrome with RV failure. IIb C\nPhosphodiesterase 3 inhibitors may be considered in patients with long-term mechanical circulatory support with postoperative low cardiac output syndrome and RV failure. IIb C [332, 333]\nThe use of levosimendan in case of postoperative low cardiac output syndrome may be considered. IIb A [334, 335]\nPostoperative mechanical ventilation\nAvoidance of hypercarbia that increases pulmonary artery pressure and RV afterload is recommended. I C\nBleeding and transfusion management\nIf mediastinal drainage exceeds 150–200 ml/h in the early postoperative phase, surgical re-exploration should be considered. IIa C\nActivated recombinant factor VII may be considered as a salvage therapy for intractable haemorrhage after correction of bleeding risk factors and after exclusion of a surgically treatable cause of bleeding. IIb C [336, 337]"}
MyTest
{"project":"MyTest","denotations":[{"id":"31100109-23849522-28905402","span":{"begin":490,"end":493},"obj":"23849522"},{"id":"31100109-23352391-28905403","span":{"begin":706,"end":708},"obj":"23352391"},{"id":"31100109-17164018-28905404","span":{"begin":710,"end":713},"obj":"17164018"},{"id":"31100109-23849522-28905405","span":{"begin":1282,"end":1285},"obj":"23849522"},{"id":"31100109-24332922-28905406","span":{"begin":1287,"end":1290},"obj":"24332922"},{"id":"31100109-24621873-28905407","span":{"begin":1292,"end":1295},"obj":"24621873"},{"id":"31100109-28087104-28905408","span":{"begin":1386,"end":1389},"obj":"28087104"},{"id":"31100109-22727248-28905409","span":{"begin":1556,"end":1559},"obj":"22727248"},{"id":"31100109-27207191-28905410","span":{"begin":1715,"end":1716},"obj":"27207191"},{"id":"31100109-20200382-28905411","span":{"begin":1718,"end":1721},"obj":"20200382"},{"id":"31100109-27207191-28905412","span":{"begin":1812,"end":1813},"obj":"27207191"},{"id":"31100109-20200382-28905413","span":{"begin":1815,"end":1818},"obj":"20200382"},{"id":"31100109-27207191-28905414","span":{"begin":2014,"end":2015},"obj":"27207191"},{"id":"31100109-23352391-28905415","span":{"begin":2017,"end":2019},"obj":"23352391"},{"id":"31100109-21037469-28905416","span":{"begin":2021,"end":2024},"obj":"21037469"},{"id":"31100109-28320259-28905417","span":{"begin":2451,"end":2454},"obj":"28320259"},{"id":"31100109-28316276-28905418","span":{"begin":2456,"end":2459},"obj":"28316276"},{"id":"31100109-23531278-28905419","span":{"begin":2989,"end":2992},"obj":"23531278"},{"id":"31100109-17617902-28905420","span":{"begin":2994,"end":2997},"obj":"17617902"}],"namespaces":[{"prefix":"_base","uri":"https://www.uniprot.org/uniprot/testbase"},{"prefix":"UniProtKB","uri":"https://www.uniprot.org/uniprot/"},{"prefix":"uniprot","uri":"https://www.uniprot.org/uniprotkb/"}],"text":"Recommendation Class Level References\nMonitoring\nIn postoperative patients with mechanical circulatory support, continuous electrocardiography, pulse oximetry, central venous pressure and invasive arterial blood pressure monitoring are recommended. I C\nMiniaturized transoesophageal echocardiographic probes that can be maintained in the oesophagus in situ for up to 72 h may be considered to assist in the management of fluid resuscitation and to diagnose complications. IIb C [317]\nA pulmonary artery catheter should be considered to assist in the management of fluid resuscitation and to diagnose complications in patients receiving an LVAD and at risk of postoperative RV failure. IIa C [71, 318]\nTranspulmonary thermodilution and pulse contour-derived measurement of cardiac output are inadequate in continuous-flow ventricular assist device and biventricular assist device settings and are therefore not recommended. III C\nPostoperative laboratory monitoring, including daily measurement of plasma free haemoglobin and lactate dehydrogenase, is recommended. I C\nRight ventricular failure in patients with a left ventricular assist device\nRegular echocardiographic scans should be considered to monitor RV function in patients supported by an LVAD. IIa C [317, 319, 320]\nEchocardiography is recommended to guide weaning from temporary RV support. I B [321, 322]\nInhaled NO, epoprostenol (or prostacyclin) and phosphodiesterase 5 inhibitors may be considered to reduce right heart failure after LVAD implantation. IIb C [323–327]\nInotrope and vasopressor support\nNorepinephrine should be considered as a first-line vasopressor in case of postoperative hypotension or shock. IIa B [9, 328, 329]\nDopamine may be considered in case of postoperative hypotension or shock. IIb B [9, 328, 329]\nThe combination of norepinephrine and dobutamine should be considered instead of epinephrine in case of postoperative hypotension and low cardiac output syndrome with RV failure. IIa C [9, 71, 330, 331]\nEpinephrine may be considered in case of postoperative hypotension and low cardiac output syndrome with RV failure. IIb C\nPhosphodiesterase 3 inhibitors may be considered in patients with long-term mechanical circulatory support with postoperative low cardiac output syndrome and RV failure. IIb C [332, 333]\nThe use of levosimendan in case of postoperative low cardiac output syndrome may be considered. IIb A [334, 335]\nPostoperative mechanical ventilation\nAvoidance of hypercarbia that increases pulmonary artery pressure and RV afterload is recommended. I C\nBleeding and transfusion management\nIf mediastinal drainage exceeds 150–200 ml/h in the early postoperative phase, surgical re-exploration should be considered. IIa C\nActivated recombinant factor VII may be considered as a salvage therapy for intractable haemorrhage after correction of bleeding risk factors and after exclusion of a surgically treatable cause of bleeding. IIb C [336, 337]"}
0_colil
{"project":"0_colil","denotations":[{"id":"31100109-23849522-7342","span":{"begin":490,"end":493},"obj":"23849522"},{"id":"31100109-23352391-7343","span":{"begin":706,"end":708},"obj":"23352391"},{"id":"31100109-17164018-7344","span":{"begin":710,"end":713},"obj":"17164018"},{"id":"31100109-23849522-7345","span":{"begin":1282,"end":1285},"obj":"23849522"},{"id":"31100109-24332922-7346","span":{"begin":1287,"end":1290},"obj":"24332922"},{"id":"31100109-24621873-7347","span":{"begin":1292,"end":1295},"obj":"24621873"},{"id":"31100109-28087104-7348","span":{"begin":1386,"end":1389},"obj":"28087104"},{"id":"31100109-22727248-7349","span":{"begin":1556,"end":1559},"obj":"22727248"},{"id":"31100109-27207191-7350","span":{"begin":1715,"end":1716},"obj":"27207191"},{"id":"31100109-20200382-7351","span":{"begin":1718,"end":1721},"obj":"20200382"},{"id":"31100109-27207191-7352","span":{"begin":1812,"end":1813},"obj":"27207191"},{"id":"31100109-20200382-7353","span":{"begin":1815,"end":1818},"obj":"20200382"},{"id":"31100109-27207191-7354","span":{"begin":2014,"end":2015},"obj":"27207191"},{"id":"31100109-23352391-7355","span":{"begin":2017,"end":2019},"obj":"23352391"},{"id":"31100109-21037469-7356","span":{"begin":2021,"end":2024},"obj":"21037469"},{"id":"31100109-28320259-7357","span":{"begin":2451,"end":2454},"obj":"28320259"},{"id":"31100109-28316276-7358","span":{"begin":2456,"end":2459},"obj":"28316276"},{"id":"31100109-23531278-7359","span":{"begin":2989,"end":2992},"obj":"23531278"},{"id":"31100109-17617902-7360","span":{"begin":2994,"end":2997},"obj":"17617902"}],"text":"Recommendation Class Level References\nMonitoring\nIn postoperative patients with mechanical circulatory support, continuous electrocardiography, pulse oximetry, central venous pressure and invasive arterial blood pressure monitoring are recommended. I C\nMiniaturized transoesophageal echocardiographic probes that can be maintained in the oesophagus in situ for up to 72 h may be considered to assist in the management of fluid resuscitation and to diagnose complications. IIb C [317]\nA pulmonary artery catheter should be considered to assist in the management of fluid resuscitation and to diagnose complications in patients receiving an LVAD and at risk of postoperative RV failure. IIa C [71, 318]\nTranspulmonary thermodilution and pulse contour-derived measurement of cardiac output are inadequate in continuous-flow ventricular assist device and biventricular assist device settings and are therefore not recommended. III C\nPostoperative laboratory monitoring, including daily measurement of plasma free haemoglobin and lactate dehydrogenase, is recommended. I C\nRight ventricular failure in patients with a left ventricular assist device\nRegular echocardiographic scans should be considered to monitor RV function in patients supported by an LVAD. IIa C [317, 319, 320]\nEchocardiography is recommended to guide weaning from temporary RV support. I B [321, 322]\nInhaled NO, epoprostenol (or prostacyclin) and phosphodiesterase 5 inhibitors may be considered to reduce right heart failure after LVAD implantation. IIb C [323–327]\nInotrope and vasopressor support\nNorepinephrine should be considered as a first-line vasopressor in case of postoperative hypotension or shock. IIa B [9, 328, 329]\nDopamine may be considered in case of postoperative hypotension or shock. IIb B [9, 328, 329]\nThe combination of norepinephrine and dobutamine should be considered instead of epinephrine in case of postoperative hypotension and low cardiac output syndrome with RV failure. IIa C [9, 71, 330, 331]\nEpinephrine may be considered in case of postoperative hypotension and low cardiac output syndrome with RV failure. IIb C\nPhosphodiesterase 3 inhibitors may be considered in patients with long-term mechanical circulatory support with postoperative low cardiac output syndrome and RV failure. IIb C [332, 333]\nThe use of levosimendan in case of postoperative low cardiac output syndrome may be considered. IIb A [334, 335]\nPostoperative mechanical ventilation\nAvoidance of hypercarbia that increases pulmonary artery pressure and RV afterload is recommended. I C\nBleeding and transfusion management\nIf mediastinal drainage exceeds 150–200 ml/h in the early postoperative phase, surgical re-exploration should be considered. IIa C\nActivated recombinant factor VII may be considered as a salvage therapy for intractable haemorrhage after correction of bleeding risk factors and after exclusion of a surgically treatable cause of bleeding. IIb C [336, 337]"}
2_test
{"project":"2_test","denotations":[{"id":"31100109-23849522-28905402","span":{"begin":490,"end":493},"obj":"23849522"},{"id":"31100109-23352391-28905403","span":{"begin":706,"end":708},"obj":"23352391"},{"id":"31100109-17164018-28905404","span":{"begin":710,"end":713},"obj":"17164018"},{"id":"31100109-23849522-28905405","span":{"begin":1282,"end":1285},"obj":"23849522"},{"id":"31100109-24332922-28905406","span":{"begin":1287,"end":1290},"obj":"24332922"},{"id":"31100109-24621873-28905407","span":{"begin":1292,"end":1295},"obj":"24621873"},{"id":"31100109-28087104-28905408","span":{"begin":1386,"end":1389},"obj":"28087104"},{"id":"31100109-22727248-28905409","span":{"begin":1556,"end":1559},"obj":"22727248"},{"id":"31100109-27207191-28905410","span":{"begin":1715,"end":1716},"obj":"27207191"},{"id":"31100109-20200382-28905411","span":{"begin":1718,"end":1721},"obj":"20200382"},{"id":"31100109-27207191-28905412","span":{"begin":1812,"end":1813},"obj":"27207191"},{"id":"31100109-20200382-28905413","span":{"begin":1815,"end":1818},"obj":"20200382"},{"id":"31100109-27207191-28905414","span":{"begin":2014,"end":2015},"obj":"27207191"},{"id":"31100109-23352391-28905415","span":{"begin":2017,"end":2019},"obj":"23352391"},{"id":"31100109-21037469-28905416","span":{"begin":2021,"end":2024},"obj":"21037469"},{"id":"31100109-28320259-28905417","span":{"begin":2451,"end":2454},"obj":"28320259"},{"id":"31100109-28316276-28905418","span":{"begin":2456,"end":2459},"obj":"28316276"},{"id":"31100109-23531278-28905419","span":{"begin":2989,"end":2992},"obj":"23531278"},{"id":"31100109-17617902-28905420","span":{"begin":2994,"end":2997},"obj":"17617902"}],"text":"Recommendation Class Level References\nMonitoring\nIn postoperative patients with mechanical circulatory support, continuous electrocardiography, pulse oximetry, central venous pressure and invasive arterial blood pressure monitoring are recommended. I C\nMiniaturized transoesophageal echocardiographic probes that can be maintained in the oesophagus in situ for up to 72 h may be considered to assist in the management of fluid resuscitation and to diagnose complications. IIb C [317]\nA pulmonary artery catheter should be considered to assist in the management of fluid resuscitation and to diagnose complications in patients receiving an LVAD and at risk of postoperative RV failure. IIa C [71, 318]\nTranspulmonary thermodilution and pulse contour-derived measurement of cardiac output are inadequate in continuous-flow ventricular assist device and biventricular assist device settings and are therefore not recommended. III C\nPostoperative laboratory monitoring, including daily measurement of plasma free haemoglobin and lactate dehydrogenase, is recommended. I C\nRight ventricular failure in patients with a left ventricular assist device\nRegular echocardiographic scans should be considered to monitor RV function in patients supported by an LVAD. IIa C [317, 319, 320]\nEchocardiography is recommended to guide weaning from temporary RV support. I B [321, 322]\nInhaled NO, epoprostenol (or prostacyclin) and phosphodiesterase 5 inhibitors may be considered to reduce right heart failure after LVAD implantation. IIb C [323–327]\nInotrope and vasopressor support\nNorepinephrine should be considered as a first-line vasopressor in case of postoperative hypotension or shock. IIa B [9, 328, 329]\nDopamine may be considered in case of postoperative hypotension or shock. IIb B [9, 328, 329]\nThe combination of norepinephrine and dobutamine should be considered instead of epinephrine in case of postoperative hypotension and low cardiac output syndrome with RV failure. IIa C [9, 71, 330, 331]\nEpinephrine may be considered in case of postoperative hypotension and low cardiac output syndrome with RV failure. IIb C\nPhosphodiesterase 3 inhibitors may be considered in patients with long-term mechanical circulatory support with postoperative low cardiac output syndrome and RV failure. IIb C [332, 333]\nThe use of levosimendan in case of postoperative low cardiac output syndrome may be considered. IIb A [334, 335]\nPostoperative mechanical ventilation\nAvoidance of hypercarbia that increases pulmonary artery pressure and RV afterload is recommended. I C\nBleeding and transfusion management\nIf mediastinal drainage exceeds 150–200 ml/h in the early postoperative phase, surgical re-exploration should be considered. IIa C\nActivated recombinant factor VII may be considered as a salvage therapy for intractable haemorrhage after correction of bleeding risk factors and after exclusion of a surgically treatable cause of bleeding. IIb C [336, 337]"}